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Background: In recent years, nasal intermittent positive pressure ventilation
(NIPPV) has been growing in popularity as a form of noninvasive ventilation for
respiratory support in the initial treatment of neonates with surfactant (SF) defi-
ciency. The combination of this type of ventilation with noninvasive SF adminis-
tration (by nebulization) is an attractive treatment option for respiratory distress
syndrome (RDS)‐associated pathophysiology of the neonatal lungs. In this study, we
aimed to test the tolerability and efficacy of SF nebulization during NIPPV for the
treatment of neonatal RDS.
Methods: Spontaneously‐breathing newborn piglets (n = 6/group) with bronch-
oalveolar lavage (BAL)‐induced RDS were assigned to receive during NIPPV
(180min): poractant alfa (400mg/kg) via an investigational customized vibrating‐
membrane nebulizer (eFlow‐Neos) or poractant alfa (200mg/kg) as a bolus using the
Insure method or no surfactant (controls).
Measurement and results: We assessed pulmonary, hemodynamic and cerebral
effects and performed histological analysis of lung and brain tissue. After repeated
BAL, newborn piglets developed severe RDS (FiO2: 1, pH < 7.2, PaCO2 > 70mmHg,
PaO2< 70mmHg, Cdyn < 0.5 ml/cmH2O/kg). In both SF‐treated groups, we observed
rapid improvement in pulmonary status and also similar hemodynamic, cerebral
behavior, and lung and brain injury scores.
Conclusion: Our results in newborn piglets with severe BAL‐induced RDS show the
administration of nebulized poractant alfa using the eFlow‐Neos nebulizer during
NIPPV to be well tolerated and efficacious, suggesting that this noninvasive SF
administration option should be explored further.
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1 | INTRODUCTION
Over recent years, the approaches used for surfactant (SF) ad-
ministration and ventilation in neonatal intensive care units
(NICUs) have changed greatly seeking to minimize the use of
invasive mechanical ventilation (MV) for the treatment of re-
spiratory distress syndrome (RDS). New approaches that have
emerged for SF administration include the intubation–
SF–extubation (Insure) method, the less invasive surfactant ad-
ministration (LISA) also known as minimally invasive SF therapy
(MIST) methods, involving intratracheal SF instillation using a
thin catheter (e.g., vascular catheter or nasogastric tube), and
also various techniques not yet approved, such as nebulization,
pharyngeal administration, and laryngeal mask airway‐guided
administration.1–3 Of these options, the least invasive way to
administer SF is nebulization, which avoids the risks related to
laryngoscopy and bolus fluid therapy.2,4 An investigational cus-
tomized nebulizer, based on vibrating‐membrane technology
(eFlow‐Neos Nebulizer; Pari Pharma GmbH) and miniaturized for
use in neonates, has been shown to deliver therapeutically useful
doses of SF to the lungs.5–8 In particular, its clinical effects were
shown to be long lasting when the SF was administered at a dose
of 400 mg/kg,9,10 and after receiving only 200 mg/kg, neonates
with mild RDS were less likely to need MV.11
On the other hand, the use of noninvasive ventilation (NIV)
as the primary mode of respiratory support in spontaneously
breathing preterm infants with RDS is becoming more widely
accepted. The two NIV techniques most commonly used in NICUs
are nasal continuous positive airway pressure (NCPAP) and nasal
intermittent positive pressure ventilation (NIPPV). In a small but
randomized study in premature infants on either NCPAP or
NIPPV, the latter was associated with less need for MV and SF
treatment (administered using a LISA/MIST technique) in the
first 72 h after birth.12 High rates of lung deposition of aero-
solized SF during NIPPV were observed in a study in newborn
piglets6; however, though several studies have explored com-
bining nebulized SF with NCPAP, this being the most commonly
used ventilation strategy,13,14 only one clinical study has been
conducted so far with NIPPV.15
Our hypothesis was that the combination of NIPPV and SF
nebulization, using the aforementioned eFlow‐Neos nebulizer,
would produce an improvement in physiological response similar
to that achieved by administering SF using the Insure method.
The aim of this study was to assess tolerability and efficacy of
SF nebulization with this device applied while using NIPPV
for NIV in the treatment of neonatal RDS. Specifically, in
spontaneously‐breathing newborn piglets with bronchoalveolar
lavage (BAL)‐induced RDS, we investigated the acute response to
the combination of these two noninvasive treatments in terms of
gas exchange and hemodynamics, as well as oxygen metabolism
and brain and lung injury scores.
2 | MATERIALS AND METHODS
2.1 | Animal preparation
All experiments were conducted following a protocol that com-
plies with Spanish and European regulations for research with
animals (UE2010/63‐RD53/2013) and was approved by the
Ethics Committee for Animal Welfare of Biocruces Bizkaia
Health Research Institute. The methods are similar to those in
our previous study exploring SF dose–response relationships in
the same animal model and are described in detail elsewhere.16
In brief, 2‐ to 4‐day‐old newborn piglets17–19 were sedated
with ketamine (15 mg/kg), diazepam (2 mg/kg) and atropine
(0.05 mg/kg) i.m. and anesthetized with sevoflurane (2%–3%).
They were ventilated with a positive pressure ventilator (VIP
Bird; Bird Products Corp.) through a cuffed endotracheal tube
(ET) and the initial settings were: FiO2 = 0.21–0.28, respiratory
frequency (fR)=28 breaths/min, positive end‐expiratory
pressure (PEEP) = 3cmH2O, and positive inspiratory pressure
(PIP) = 9–11 cmH2O adjusted to achieve a tidal volume (VT) =
8–10 ml/kg.9,16,20
For monitoring mean arterial blood pressure (MABP) and
heart rate (HR) and obtaining blood samples for gas analysis, an
arterial catheter was inserted into the femoral artery. Further,
for administering fluid therapy and obtaining venous blood
samples, a 5Fr dual‐lumen catheter was placed in the jugular
vein. An ultrasonic flow probe (Transonic Systems Inc.) was used
to measure blood flow in the right common carotid as a proxy for
cerebral blood flow. Heat lamps were used to keep rectal tem-
perature at 38–39°C.
2.2 | Study design including induction of lung
injury
BAL (30ml/kg; 37°C with FiO2: 1) was performed to induce SF‐
deficient lung injury.20,21 At the end of BAL procedure, positive
pressure ventilation settings were FiO2 = 1.0
21–23 and PEEP = 5
cmH2O, and to avoid barotrauma, fR and PIP were adjusted to a
maximum of 42 breaths/min and 25 cmH2O, to maintain VT = 8–10
ml/kg. Lavage procedures were repeated (every 5min) until arterial
blood partial pressure of oxygen (PaO2) <100mmHg. After allowing
the piglets to stabilize for 30min on positive pressure ventilation,
they received an i.v. bolus dose of 20mg/kg of caffeine citrate
(Peyona 20mg/ml; Chiesi Farmaceutici, Parma) to stimulate spon-
taneous breathing and were fitted with short binasal prongs (made
by cutting and joining two pieces of ET, with an internal diameter of
3–5mm and length of 4 cm, matched to the size of our piglets' nasal
orifice). Having established spontaneous breathing, piglets were
randomly assigned, using a sealed envelope method, to one of three
groups:
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‐ NIPPV alone group (n = 6): the ET was removed and animals were
maintained on NIPPV for 180min, without SF treatment.
‐ NIPPV‐Insure (Insure) group (n = 6): 200mg/kg of poractant alfa
(Curosurf; Chiesi Farmaceutici, Parma) was administered through
the ET, which was then immediately removed, and animals were
maintained on NIPPV and followed up for 180min from SF
administration.
‐ NIPPV‐Neb‐Surf (NS) group (n = 6): the ET was removed, a volume
of 400mg/kg of poractant alfa was placed in the reservoir and SF
was administered using the eFlow‐Neos nebulizer (Pari Pharma)
placed between the prongs and the NIPPV circuit, the nebulizer
was removed (immediately after SF nebulization), and animals
were maintained on NIPPV and followed up for 180min from SF
administration.
Initial NIPPV settings were: fR of 40 breaths/min; PEEP 5 cmH2O
and PIP 15–17 cmH2O at FiO2 = 1. These were then adjusted based
on individual animal's pulmonary status, seeking to keep PaO2 and
PaCO2 within the ranges of 80–100mmHg and 35–45mmHg, re-
spectively. To avoid oxygen induced lung injury, FiO2 was reduced as
soon as PaO2 improved to maintain values within the range of
80–100mmHg.
2.3 | Physiological measurements
In all randomized piglets, we measured directly or calculated the
following measurements:
‐ Arterial pH, PaO2, PaO2/FiO2 ratio, PaCO2 and base excess, lactic acid,
and glucose (GemPremier4000; Instrumentation Laboratory);
‐ Hemodynamic parameters, namely, HR, MABP, and carotid
blood flow;
‐ Oxygen delivery (OD), oxygen consumption (VO2) and intrapulmonary
shunt ratio (Qs/Qt) (IntelliVue Monitor; Philips Medical System), using
the following equation: Qs/Qt (%) = 100× (1.34 ×Hb+0.0031×
PAO2−CaO2)/(1.34 ×Hb+0.0031×PAO2−CvO2), where Hb is he-
moglobin (g/dl); PAO2 = FiO2 × (Patmospheric−47)−PaCO2; CaO2 is arterial
O2 content and CvO2 is mixed venous O2 content.
All these measurements were obtained at the following time
points: immediately after surgery; on intubation at baseline (basal
values); immediately after inducing RDS (BAL values); after the sta-
bilization (ST) period (to confirm respiratory failure); immediately
after extubation; 15 and 30min after the start of NIPPV, and then
every 30min during NIPPV until the end of the experiment, at
180min. The measurements in NS group started from the beginning
of nebulization for first 15–30min measurement on NIPPV.
In addition, airway flow, mean airway pressure and VT with a
flow sensor (placed between the circuit and the ET), and dynamic
compliance (Cdyn), VT and airway resistance with a computerized
system (M1014A; Philips Medical System) were measured at base-
line; immediately after inducing RDS; and after the ST period. In all
animals, it was not feasible to measure lung mechanics after ex-
tubation, when NIPPV was established. Hence, at the end of the
experiment, they were re‐intubated and connected to mechanical
ventilation (using the same settings as at baseline), and after 5 min of
ST, lung mechanics were measured.
2.4 | Lung tissue analysis
After animal sacrifice, the lungs were removed and perfused with saline.
For biochemical analysis, the left lung was isolated, occluded, submerged
in liquid nitrogen and stored at −80°C until use, and for histological
analysis, the right lung was fixed in 4% formalin at 15 cmH2O.
Samples were taken from the frozen lungs to measure interleukin‐8
(IL‐8), IL‐1B, and tumor necrosis factor‐α (TNF‐α) levels using specific
enzyme‐linked immunosorbent assay kits for porcine interleukins
(Abnova), and protein levels using the Bradford method (Bio‐Rad).24 The
formalin‐fixed tissue was cut into 5‐µm sections, which were placed on
slides and stained with hematoxylin‐eosin. Lung injury was assessed with
light microscopy by a pathologist blinded to group allocation who rated
the extent of injury using a semi‐quantitative scoring system. As
described elsewhere, alveolar and interstitial hemorrhage, alveolar and
interstitial inflammation, atelectasis, edema, and necrosis were each
scored on a 0‐ to 4‐point scale: 0 indicating no lung injury; 1, 2, and
3 injury to 25%, 50%, and 75% of the field, respectively; and 4 injury
across the field.25,26
2.5 | Brain tissue analysis
For histological analysis, the brain was fixed (4% formalin) and divided
into brain stem and cerebellum, cortex, and inner regions (striatum,
thalamus, and hippocampus). As for lung injury, brain injury was assessed
with light microscopy by a pathologist blinded to group allocation who
rated the extent of injury using a semi‐quantitative scoring system. As
described elsewhere, edema, hemorrhage, inflammation, infarction and
necrosis were each scored on a 0‐ to 3‐point scale: 0 indicating no injury;
and 1, 2, and 3 mild, moderate, and severe injury across the field. In total,
20 fields were analyzed and more than five necrotic cells/field was
considered to indicate neuronal necrosis (score range: 0–20).16,26
2.6 | Statistical analysis
Data were expressed as mean± SEM. Levene's test was used to assess
the homogeneity of variance between the different treatments and the
Kolmogorov–Smirnov test to assess whether the data were normally
distributed (JMP8; Statistical Discovery, SAS). One‐ and two‐way analysis
of variance were performed to analyze gas exchange, hemodynamics,
oxygen metabolism, and lung mechanics by group and time of repeated
measures. The Wilcoxon test was used to assess lung biochemical results
and injury score and brain injury score. A p value of less than .05 was
considered significant.
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3 | RESULTS
The 18 newborn piglets used in the study were from different litters
but similar in age (3 ± 1days) and size (2.0 ± 0.1 kg). To induce ap-
propriately severe lung injury, at least 13 BALs (range: 13–15) were
required (resulting parameters: PaO2 < 100mmHg; NIPPV:
61 ± 2mmHg; Insure: 64 ± 3mmHg; NS: 63 ± 3mmHg). Differences
between groups in the numbers of BALs required and the volume of
lavage fluid recovered did not reach significance. The mean SF
nebulization time was 48 ± 1min.
3.1 | Pulmonary outcomes
3.1.1 | Gas exchange and lung mechanics
Values of pH, PaO2/FiO2, PaCO2, and Cdyn were similar across the
groups at baseline, after induction of SF‐deficient lung injury and
after 30min of ST (Table 1 and Figure 1). In all groups, BAL was
followed by significant decreases in PaO2/FiO2 (Figure 1A), Cdyn
(Figure 1B), and pH (Table 1) and a significant increase in PaCO2
(Figure 1C), consistent with severe RDS.
Improvements were observed in PaO2/FiO2 ratio, PaCO2, and pH
in all groups. Comparing Insure and NIPPV alone, the parameters
improved more rapidly in the Insure group (Figure 1; Table 1). Spe-
cifically, RDS had resolved in the Insure group by the end of the
experiment (PaO2/FiO2 ratio > 350mmHg), whereas animals given
only NIPPV continued to have mild‐to‐moderate RDS (PaO2/FiO2
ratio < 280mmHg). In line with the improvements observed in the
Insure group, the values of these parameters also improved sig-
nificantly after the administration of 400mg/kg of nebulized SF.
Further, in the NS group, PaCO2 was ≥50mmHg during the neb-
ulization period (Figure 1C), and decreased rapidly after nebulizer
removal, carbon dioxide returning to within the normal range by
60min after starting nebulization. Notably, PaCO2 remained higher
in animals in the NIPPV alone group than those in the SF‐treated
groups throughout the experiment.
Regarding lung compliance, Cdyn returned to or close to baseline
(80%–85%) in both SF‐treated groups, the extent of recovery being
significantly greater than in the NIPPV alone group (Cdynreturning to
60% of baseline). In contrast, VT and resistance parameters did not
differ between groups (data not shown).
For the first 30min after SF administration, respiratory fre-
quency was significantly higher in both SF‐treated groups (Table 1).
After that, no significant between‐group differences were detected.
3.1.2 | Lung inflammatory markers and lung injury
After 3 h on NIPPV, both SF‐treated groups had lower cytokine le-
vels than those seen in animals only given NIPPV. Specifically,
compared to levels in the NIPPV alone group (IL‐8: 33 ± 3 pg/mgprot;
TNF‐α: 38 ± 3 pg/mgprot; IL‐1β: 360 ± 27 pg/mgprot), Insure group
animals had significantly lower levels of all cytokines (IL‐8: 19 ± 2
pg/mgprot; TNF‐α: 27 ± 2 pg/mgprot; IL‐1β: 260 ± 28 pg/mgprot),
while NS group animals had significantly lower levels of IL‐8 and
TNF‐α (IL‐8: 24 ± 3 pg/mgprot; TNF‐α: 27 ± 3 pg/mgprot), but the
difference in the case of IL‐1β did not reach significance (IL‐1β:
280 ± 25 pg/mgprot, p = .053 vs. NIPPV group). Although all values
were within normal physiological ranges, significantly more edema
and interstitial hemorrhage were observed in both SF‐treated groups
than in the NIPPV alone group (Table 2 and Figure 2).
3.2 | Intrapulmonary shunt and oxygen transport
BAL was followed by a significant increase in Qs/Qt (Figure 3A), but
none of the systemic oxygen metabolism parameters changed sig-
nificantly (Table 1). In the NIPPV alone group, there were no sig-
nificant changes in OD or VO2 after 3 h on ventilation (Table 1), and
though Qs/Qt gradually improved, it did not reach baseline
(Figure 3A). In contrast, in both SF‐treated groups, Qs/Qt recovered
to baseline by 2 h after treatment (Figure 3A). Further, VO2 values
were significantly higher in the groups receiving SF treatment as well
as NIPPV than that on NIPPV alone (Table 1), without significant
differences in OD.
3.3 | Hemodynamic assessment
Hemodynamic parameters did not differ significantly between the
groups at baseline. Further, following BAL, there were no significant
changes in MABP (Figure 3B), but the HR increased significantly
(Figure 3C). Over the study period, MABP values remained similar in
all groups studied, while HR was significantly higher in both Insure
and NS groups at 2 h after the start of treatment than in those given
NIPPV alone.
3.4 | Cerebral evaluation
In all groups, carotid blood flow increased significantly following BAL
(Figure 3D). Subsequently, during NIPPV with or without SF treatment
(i.e., in all groups), carotid blood flow decreased steadily reaching baseline
values by 1 h after the start of treatment. Further, brain injury scores
were low in all three groups, with similar scores for necrosis, edema,
hemorrhage, inflammation, and infarction for all regions studied (Table 3
and Figure 2).
4 | DISCUSSION
In our spontaneously‐breathing newborn piglet model of SF‐deficient
lung injury, we have shown that the investigational customized
eFlow‐Neos nebulizer is well‐tolerated and efficacious, in that SF
nebulization administered using this device during NIPPV is
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associated with a clinically‐relevant improvement in acute physiolo-
gical parameters, in particular, in oxygenation and lung function, and
similar pulmonary, hemodynamic and cerebral and lung behavior to
that observed with SF administration by the Insure method followed
by NIPPV.
Natural SF administration is the most effective treatment
of neonatal RDS, reducing mortality and morbidity in premature
neonates. For many years, the traditional administration of SF via
endotracheal intubation, bolus SF administration and prolonged MV
has been the only approved method for administering SF in premature
neonates with RDS. In recent years, however, the use of less invasive
SF administration techniques (such as Insure, LISA/MIST, and even
nebulization) and NIV strategies as the primary mode of respiratory
support (NCPAP, NIPPV, etc.)2,4,12,27,28 have been gaining acceptance
in NICUs, seeking to avoid the side effects and risks29 associated with
more invasive approaches to SF administration and MV.
The use of less invasive SF administration techniques during
NCPAP ventilation has been evaluated in animal and clinical studies,
with positive results.1,2,4,9,10,16 Further, there is some evidence that
the positive effects observed may be enhanced if NIPPV were to be
used instead of NCPAP.12,20,30 Specifically, NCPAP only provides
continuous distending pressure, to open the lungs and thereby pre-
vent collapse of the alveoli during expiration, while NIPPV offers the
same support plus ventilator breaths delivered at a set peak pres-
sure, providing the benefits of NCPAP with less work of breathing.31
Advantages of using NIPPV compared with NCPAP have been shown
previously in infants given SF therapy with the Insure method.30,32
Consistent with these findings, in a previous study with our animal
model,20 as in the current study, we observed that improvements in
pulmonary outcomes (namely, gas exchange, lung mechanics, and
lung inflammatory markers) were more rapid and significantly
greater with NIPPV plus SF replacement therapy administered using
the Insure method than with NIPPV alone.20 Further, benefits of
NIPPV over NCPAP were observed in a small randomized study in
preterm infants, with a reduction in the need for MV and also for SF
treatment (administered with a LISA/MIST technique) in the first
72 h after birth.12 Nonetheless, only one previous study has in-
vestigated a minimally invasive method for SF administration (e.g.,
using a nebulizer) during NIPPV to treat neonatal RDS.15 Although
just 10% of patients were treated with SF delivered via a nebulizer
plus NIPPV, the authors concluded that SF nebulization using non-
invasive respiratory support reduced rate of intubation and SF in-
stillation by nearly one‐half.15
Nebulization of SF during NCPAP treatment using the eFlow
Neos nebulizer has been investigated in randomized control trial in
premature infants,11 as well as in animals,5,6,9,10,16,16,33 the results
suggesting that this approach is both safe and feasible. This nebulizer
has been customized considering the distinctive characteristics of SF
(in particular, its lipid‐protein composition and high viscosity) and has
been shown to enhance the delivery of SF to the neonatal respiratory
system during NCPAP, studies having documented appropriate
particle sizes (2.5–3.5 µm), high distal airway delivery efficacies
F IGURE 1 PaO2/FIO2 ratio, dynamic compliance (Cdyn) and
PaCO2 in newborn piglets with bronchoalveolar lavage‐induced
respiratory distress syndrome treated with noninvasive
ventilation (nasal intermittent positive pressure ventilation
[NIPPV]) with or without surfactant therapy (administered using
the Insure method or nebulization [nebulized surfactant {NS}]).
Values of (A) PaO2/FIO2, (B) Cdyn, and (C) PaCO2 in the NIPPV alone
(black square), insure (white square), and NS (white circle) groups.
Cdyn value at 180 min was measured after the reintubation of the
animals at the end of the study. §p < .05 versus baseline; *p < .05
versus NIPPV alone group and #p < .05 versus Insure group (one‐
way analysis of variance); $p < .05 versus NIPPV alone group and
&p < .05 versus Insure group (two‐way analysis of variance).
Values are expressed as mean ± SEM. 30 ST, 30‐min period of
stabilization
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TABLE 2 Total lung injury scores in in BAL‐induced RDS newborn piglets treated with nasal continuous positive airway pressure (NIPPV)
without or with surfactant treatment, using the Insure method, or NS









NIPPV 0.72 ± 0.19 0 0 0.66 ± 0.18 1.28 ± 0.21 0 0 2.67 ± 0.46
Insure 1.06 ± 0.18 0 0.20 ± 0.10* 1.00 ± 0.25 1.47 ± 0.21 0.06 ± 0.06 0.20 ± 0.11* 4.00 ± 0.56
NS 0.56 ± 0.18 0 0.33 ± 0.11* 0.94 ± 0.24 1.39 ± 0.26 0.06 ± 0.06 0.28 ± 0.11* 3.39 ± 0.62
Note: Values are expressed as mean ± SEM. Statistical differences *p < .05 versus NIPPV group were assessed using analysis of variance.
Abbreviations: BAL, bronchoalveolar lavage; NIPPV, nasal intermittent positive pressure ventilation; NS, nebulized surfactant; RDS, respiratory distress
syndrome.
F IGURE 2 Photomicrographs (×200 magnification) of representative sections of the (A–C) lung and (D–F) brain from animals in the NIPPV
alone, Insure, and NS groups, respectively. Lung sections were cut from the middle lobe of the lung and brain sections from the striatum. NIPPV,
nasal intermittent positive pressure ventilation; NS, nebulized surfactant [Color figure can be viewed at wileyonlinelibrary.com]
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(of >14%) and maintenance of SF activity after nebulization.5,34,35
Testing the lung deposition of nebulized SF in healthy newborn
piglets during NIPPV, high lung deposition of SF was also observed
(>20%), similar to that reported during NCPAP.6
This study in spontaneously breathing newborn piglets with SF‐
deficient lung injury was designed to investigate the tolerability and
efficacy of administering nebulized poractant alfa (at a dose of
400mg/kg selected based on the results of a previous study)16
during NIPPV for the treatment of neonatal RDS. We observed
better oxygenation, intrapulmonary shunt and lung mechanics in
animals treated with SF by either of the methods of administration
studied, namely, the Insure method and nebulization, than in un-
treated controls. A small delay in the improvement in oxygenation
(not statistically significant) was observed in NS group compared to
the Insure group, attributed to the time required for nebulized SF to
reach the lung. Although one clinical trial has administered SF neb-
ulization during NIV (including NIPPV) with positive results,15 most
of the findings on nebulized SF during NIV have been obtained when
this treatment was administered during NCPAP. As in our study,
similar pulmonary improvements have been previously observed
F IGURE 3 Intrapulmonary shunt ratio (Qs/Qt) and carotid blood flow (D) in newborn piglets with bronchoalveolar lavage‐induced
respiratory distress syndrome treated with noninvasive ventilation (NIPPV) with or without surfactant therapy (administered using the Insure
method or nebulisation [NS]). (A) Mean Qs/Qt and (B) mean carotid blood flow values in the NIPPV alone (black square), Insure (white square),
and NS (white circle) groups. §p < .05 versus baseline; *p < .05 versus NIPPV alone group and #p < .05 versus Insure group (one‐way analysis of
variance); $p < .05 versus NIPPV alone group and &p < .05 versus Insure group (two‐way analysis of variance). Values are expressed as
mean ± SEM. 30 ST, 30‐min period of stabilization; NIPPV, nasal intermittent positive pressure ventilation; NS, nebulized surfactant
TABLE 3 Total brain injury scores in
BAL‐induced RDS newborn piglets treated
with NIPPV without or with surfactant
treatment, using the Insure method NS
Groups Necrosis Edema Inflammation Hemorrhage Infarct
NIPPV 8 (0–16) 0.4 (0–1) 0.3 (0–1) 0 (0–0) 0 (0–0)
Insure 8 (2–16) 0.4 (0–1) 0.3 (0–1) 0 (0–0) 0 (0–0)
NS 9 (0–17) 0.3 (0–1) 0.2 (0–1) 0 (0–0) 0 (0–0)
Note: No statistical differences were observed. Values are expressed as mean ± range.
Abbreviations: BAL, bronchoalveolar lavage; NIPPV, nasal intermittent positive pressure ventilation;
NS, nebulized surfactant; RDS, respiratory distress syndrome.
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during NCPAP plus SF nebulization in short‐10,16 and long‐term9,11
follow‐up studies. Moreover, a benefit of nebulization of natural SF
(with known anti‐inflammatory properties)36 was also observed
when assessing lung inflammatory mediators, with lung IL‐8 and
TNF‐α levels being similar to those with the Insure method, but
significantly lower than those observed with NIPPV alone.
In our study, the animals on NIPPV alone developed hypercarbia
and we attribute this to a lower capacity to achieve lung recruitment
after lung injury; then, as more of the lung was recruited, carbon
dioxide levels fell, though they remained somewhat higher than in
SF‐treated groups. Further, a transient increase in PaCO2 was ob-
served following SF nebulization (likely related to external dead
space), but this parameter returned to normal on nebulizer removal,
as occurred when SF nebulization was applied during NCPAP.16
Based on our pathological injury scores, it seems that SF
administration using Insure or nebulization procedures results in
higher values of edema and interstitial hemorrhage than NIPPV
alone. These higher values could be related to the effect pro-
duced by SF in the neonatal lung including a rapid improvement
in lung compliance, rapid fall in pulmonary vascular resistance,
increase in pulmonary blood flow, and so on.37 Nonetheless, as
when interpreting physiological outcomes, we should note that
lung damage may be visible (and rated with a low score) without
being clinically relevant. Specifically, data published by
Zimmermann et al.25 and our research group using the same
animal model16 suggest that all the values obtained in lung injury
score in all the groups in this study should not be considered to
reflect poor outcomes in terms of histological lung injury.
Nonetheless, longer studies are needed to confirm this.
As in previous studies,10,16 nebulization was not associated with
any other significant changes in MABP, HR or systemic oxygen me-
tabolism. Subsequently, although MABP did not change significantly
in any groups, HR and VO2 were higher in SF‐treated groups than the
NIPPV alone group, though in this group they also remained within
the physiological range as in our previous research.20 Moreover, as
previously observed with SF nebulization during NCPAP,9,16 neither
method for SF administration seemed to have a clinically significant
effect on brain injury score, confirming the safety of SF nebulization
during NIPPV.
We should recognize that this study has various limitations. In par-
ticular, we studied newborn piglets (2–4 days old) rather than premature
piglets. Although in the context of neonatal RDS, premature animal
models provide clinically relevant models of preterm neonatal physiology,
SF washout by repeated lavage has been successfully used to develop
models of acute pulmonary failure in the context of RDS in both adult
and juvenile animals.21,22,38 Moreover, one of the major limitations of the
preterm pig model is associated with the large size of the sow
(280–350 kg) and the requirement for equipment suitable for handing
such weights. Further, the resources required, in terms of expert staff
and NICU equipment to deal with the resuscitation and initiation of
noninvasive ventilation for a large number of piglets at preterm Cae-
sarean section, means that this animal model is not feasible for many
researchers. Another limitation is that, evidently, the nasal and
pharyngeal anatomy of piglets differs from that of human infants; on the
other hand, an advantage of the newborn piglet model is that brain
maturation, lung volume, and birth weights have been shown to resemble
those of newborn infants. Nonetheless, while animal models serve to
bridge the gap between clinical and laboratory research, extrapolation of
our results to humans requires caution. Further, animals were only fol-
lowed up to 3 h.
5 | CONCLUSION
Delivery of a pulmonary SF (poractant alfa) with an investigational
customized nebulizer (the eFlow‐Neos) was both well tolerated and
efficacious in acutely relieving SF deficiency in spontaneously
breathing newborn piglets on NIPPV. Nonetheless, longer studies
and clinical trials are required to assess outcomes in the long term,
such as the need for SF re‐dosing or intubation, as well as ventilation
time and physiological stability, compared to outcomes obtained with
NIPPV alone.
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